The Priority Review

Tag

NCT04963296

1 story

Stories

  1. Clinical trials

    Hoffmann-La Roche posts results of Phase III obinutuzumab study in systemic lupus erythematosus

    Results for the study were first posted on ClinicalTrials.gov on November 12, 2026. The Phase III trial enrolled 303 participants, with primary completion on September 15, 2025, and compared obinutuzumab to placebo in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard-of-care therapy.